Orion Corporation and Newel Health enter into licensing agreement for a digital therapeutic (DTx) ODD-403 (“Rohkea”) in pain
29 Enero 2024 - 3:00AM
Orion Corporation and Newel Health enter into licensing agreement
for a digital therapeutic (DTx) ODD-403 (“Rohkea”) in pain
ORION CORPORATION PRESS RELEASE 29 JANUARY 2024 at 11.00 EET
Orion Corporation and Newel Health enter into licensing
agreement for a digital therapeutic (DTx) ODD-403 (“Rohkea”) in
pain
Orion Corporation (“Orion”) and Newel Health (“Newel”) have
entered into a license agreement regarding ODD-403 (“Rohkea”), a
digital therapeutic (DTx) developed by Orion for patients suffering
from chronic pain and particularly from fear of movement and
re-injury. Under the terms of the agreement, Newel will have the
exclusive global rights to develop, manufacture and commercialise
ODD-403. Orion is entitled to receive royalty from the sales of the
product as well as sales milestone payments.
“Newel is one of the frontrunners in digital therapeutic (DTx)
applications, and we are pleased to have them as our partner in
this indication area. We believe Newel has the best expertise to
further develop and bring ODD-403 to patients,” says
Sammeli Liikkanen, Director of Digital Medicine at
Orion Corporation.
“Orion Corporation’s commitment to address medical needs through
digital innovation has been the driving force behind our ongoing
collaborations. Today we are excited to welcome ODD-403 under our
wing for further development and introduction to market, adding
Virtual Reality modalities to our growing portfolio of
partner-ready DTx solutions,” says Gerry Chillè,
Chief Strategy Officer at Newel Health.
About ODD-403ODD-403, designed to be a software
as medical device (MDSW / SaMD) under EU MDR and FDA, is built for
virtual reality (VR) devices to provide an immersive gamified
therapeutic treatment program for chronic pain patients. The
product has a selection of psychological and therapeutic modules,
from which a treatment package is composed according to the needs
of the patients. The product is designed to be flexible and to be
used as a part of multiple different treatment approaches. It also
provides information for patients and healthcare professionals. As
an example, gamified physical movements with proven safety targeted
to encourage movement can lead one to overcome the fear of
movement, and so increase activity. As showcased in the 'VIRPI'
study, ODD-403 marks a statistically significant advancement in
chronic pain management. The study revealed a notable reduction in
the Tampa Scale for Kinesiophobia scores (-4.7 points, p=0.046) and
substantial improvements in Patient Clinical Global Impression of
Change and quality of life at the end-of-intervention, compared to
placebo sham controls. Newel Health is well poised to leverage
ODD-403’s compelling clinical findings, underscoring its commitment
to delivering validated and impactful digital health solutions.
About OrionOrion is a globally operating
Finnish pharmaceutical company – a builder of well-being. We
develop, manufacture and market human and veterinary
pharmaceuticals and active pharmaceutical ingredients. Orion has an
extensive portfolio of proprietary and generic medicines and
self-care products. The core therapy areas of our pharmaceutical
R&D are oncology and pain. Proprietary products developed by
Orion are used to treat cancer, neurological diseases and
respiratory diseases, among others. Orion's net sales in 2022
amounted to EUR 1,341 million and the company had about 3,500
employees at the end of the year. Orion's A and B shares are listed
on Nasdaq Helsinki.
About Newel Health Newel Health, a leader in
digital health, develops advanced digital medicine and therapeutic
solutions, emphasizing behavioural science and user-centred design
to enhance patient care. The company has broadened its expertise in
digital, data, and scientific fields through key acquisitions.
Newel's expertise in patient-centred healthcare drives strategic
partnerships, enabling stakeholders to leverage its digital health
solutions portfolio to accelerate the development of new
applications in various therapeutic areas. Newel’s proprietary
H.Core framework ensures rapid adaptation and deployment,
optimizing investment and enhancing innovation and collaboration.
Contact
persons:Orion CorporationTerhi OrmioVice
President, CommunicationsOrion Corporationtel. +358 50 966
4646e-mail: terhi.ormio@orion.fi Newel HealthGerry
Chillè, Co-Founder and CSONewel Healthtel. +1 917.719.1911e-mail
gerry.chille@newel.healthPublisher:Orion
CorporationCommunicationsOrionintie 1A, FI-02200 Espoo,
Finlandwww.orion.fi
Orion (BIT:1ORNBV)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Orion (BIT:1ORNBV)
Gráfica de Acción Histórica
De May 2023 a May 2024